AMAG Pharmaceuticals, Inc. to Host Conference Call to Discuss Financial Results for the Quarter Ended June 30, 2009

LEXINGTON, Mass.–(BUSINESS WIRE)– AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced it will report unaudited consolidated financial results for the quarter ended June 30, 2009 after the U.S. financial markets close on July 29, 2009. The announcement will be followed by a conference call at 4:30 p.m. ET during which management will discuss the Company’s financial results, business highlights and its development programs.

To access the conference call via telephone, please dial (877) 412-6083 from the United States or (702) 495-1202 for international access. A telephone replay will be available from approximately 7:30 p.m. ET on July 29, 2009 through midnight July 31, 2009. To access a replay of the conference call, dial (800) 642-1687 from the United States or (706) 645-9291 for international access. The passcode for the live call and the replay is 20620209.

An audio webcast of the call will be available through the Investors section of the Company’s website at www.amagpharma.com. The webcast replay will be available from approximately 6:30 p.m. ET on July 30, 2009 through midnight August 31, 2009.

About AMAG Pharmaceuticals, Inc.

AMAG Pharmaceuticals, Inc. is a biopharmaceutical company that utilizes its proprietary technology for the development and commercialization of a therapeutic iron compound to treat iron deficiency anemia and novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease. AMAG recently received approval from the U.S. Food and Drug Administration to market Feraheme(TM) (ferumoxytol) Injection for the treatment of iron deficiency anemia in chronic kidney disease patients. For additional company and product information please visit www.amagpharma.com.

Feraheme(TM) is a trademark of AMAG Pharmaceuticals, Inc.

    Source: AMAG Pharmaceuticals, Inc.